Clinical Trials Logo

Filter by:
NCT ID: NCT06042556 Completed - Contraception Clinical Trials

IUD Self-Removal: Evaluating an Online Guide for Self-removal in Clinical and Non-clinical Settings

Start date: April 3, 2021
Phase: N/A
Study type: Interventional

Investigators previously developed a guide to help people with IUD self-removal. In this randomized study, the goal is to see if this guide makes it easier for IUD-users to remove their own IUDs. The main question the study aims to answer is: -Does use of the previously developed IUD self-removal guide increase rates of self removal? Participants will: - Complete a pre-study survey - Be randomized to self-removal with use of the guide or no additional resource - Self-select participation at home or in clinic - Attempt IUD self-removal either at home or in clinic - Complete a post-study survey. Investigators will compare rates of successful self-removal between those randomized to the guide to those randomized to no additional resource to see if increases success.

NCT ID: NCT06042504 Completed - Clinical trials for Stress, Psychological

Effects of Family Status of Osteopathic Medical Students on Their Perceived Level of Stress.

Start date: January 25, 2022
Phase:
Study type: Observational

The investigators are interested in studying the effects of familial obligations, including marriage, parenthood, familial caregiving, on stress levels in Osteopathic Medical Students (OMS). The investigators expect to find that having a family may increase the stress level of OMS in comparison with OMS who don't have familial obligations.

NCT ID: NCT06042400 Completed - Anxiety Clinical Trials

Trial of Written Exposure for Metastatic Cancer Patients (EASE)

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer patients may report feeling upset or haunted by imagined scenarios in a way that causes them distress and lowers their quality of life. This study aims to look at the acceptability and feasability of a writing-based intervention for adults with late-stage or recurrent cancer, or actively treated blood cancer. The EASE study uses a writing-based approach to address an individual's worst-case scenario about cancer because previous studies have shown that similar approaches have shown promise in reducing fear in early-stage cancer survivors and among adults with PTSD (posttraumatic stress disorder). The EASE study represents a novel adaptation of this foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with late stage cancers. The EASE study will include 5 weekly one-on-one online video sessions with a trained therapist where participants will be coached through writing exercises based on a worst-case scenario related to their cancer experience.

NCT ID: NCT06041646 Completed - Schizophrenia Clinical Trials

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Start date: October 12, 2023
Phase: Phase 4
Study type: Interventional

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.

NCT ID: NCT06040593 Completed - Clinical trials for HER2-negative Breast Cancer

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Start date: July 31, 2023
Phase:
Study type: Observational

There is a lack of data on clinical and patient factors that are associated with poor survival in patients with HR+ and HER2-low/negative breast cancer treated with neoadjuvant chemotherapy or endocrine therapy. This retrospective, non-interventional study is designed to assess the predictors of clinical outcomes in this patient population. No study drug will be provided as part of this study protocol.

NCT ID: NCT06040372 Completed - Healthy Clinical Trials

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Start date: March 16, 2020
Phase: Phase 1
Study type: Interventional

The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects

NCT ID: NCT06038786 Completed - Anxiety Disorders Clinical Trials

Resiliency Training on the College Campus

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

This is a waitlist controlled study examining the initial efficacy of Resilience Training among college students at an elevated risk for a severe mental illness.

NCT ID: NCT06037668 Completed - Clinical trials for Social Anxiety Disorder (SAD)

A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

BVR-100-102
Start date: September 8, 2023
Phase: N/A
Study type: Interventional

This study is to compare two Virtual Reality (VR)-based interventions, BVR-100 and BES-100, for the treatment of Social Anxiety Disorder (SAD).

NCT ID: NCT06037109 Completed - Healthy Clinical Trials

VIDAS® NEPHROCLEAR Reference Interval Study

Start date: July 18, 2023
Phase:
Study type: Observational

This is a multi-center sample analysis study in which urine samples previously collected from apparently healthy adult subjects, and subjects with stable chronic morbidities but without AKI in order to establish the reference range for the VIDAS® NEPHROCLEARâ„¢ CCL14 test.

NCT ID: NCT06036758 Completed - Acute Kidney Injury Clinical Trials

VIDAS® NEPHROCLEAR Diagnostic Accuracy Study

Start date: July 17, 2023
Phase:
Study type: Observational

This is a multi-center sample analysis study in which urine samples previously collected from persons with Stage 2 or Stage 3 Acute Kidney Injury (AKI), will be tested in order to validate the VIDAS® NEPHROCLEARâ„¢ CCL14 Test